Health Care • Medical/Dental Instruments
$5.86 ▲ +0.08
(+1.38%)
MKT CAP: $214.1M • VOL: 67.4K
52W L $5 52W H $9
PROF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $16.1M | $9.7M | $5.9M |
| YoY Revenue Growth % | +65.3% | +65.1% | — |
| Gross Profit | $11.4M | $7.0M | — |
| Gross Margin % | 70.8% | 72.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$41.3M | -$33.1M | -$28.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$42.6M | -$27.8M | -$28.3M |
| EBITDA (Normalized) | -$41.1M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$38.2M | -$23.5M | -$22.6M |
| Capital Expenditures (CapEx) | $176.0K | — | — |
| Free Cash Flow (FCF) | -$38.4M | -$23.5M | -$22.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $59.7M | $54.9M | — |
| Total Debt (Short + Long Term) | $4.5M | $2.9M | — |
| Total Stockholders' Equity | $66.4M | $60.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PROF.